Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Utah for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Utah only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Utah (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Corey Walker (NPI 1295707677)

Field	Value
Entity Type	Individual
Organization	Corey Walker
Address	1350 N 500 E
City	Logan
State	UT
ZIP	84341
Taxonomy	Rheumatology Physician
NPI Enumerated	February 1, 2006

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

This provider is effectively a single‑payer practitioner: Total Medicare revenue: $2.3M and there is no Medicaid billing on file, so Medicaid does not contribute to this clinician’s reported revenue mix. Analysts should treat Medicare as the dominant and near‑exclusive payer when evaluating volume and utilization patterns for this NPI.

Revenue is heavily concentrated in a small set of biologic drug codes: the precomputed top 3 codes account for 63.6% of this provider's total Medicare revenue, driven by J3262 ($636.4K, 27.0%), J0129 ($493K, 20.9%), and J1745 ($370.1K, 15.7%). This concentration indicates that most Medicare dollars flow through a handful of high‑cost injectable biologics rather than routine office visits.

Service‑line mix is consistent with an infusion‑focused rheumatology practice: high revenue from J3262 (tocilizumab), J0129 (abatacept), J1745 (infliximab) plus additional biologics such as J9312 (rituximab) and J1602 (golimumab) indicate frequent in‑office administration of intravenous/subcutaneous biologic therapies. The presence of infusion/chemotherapy administration codes (96413, 96415, 96365) further supports that this provider operates an infusion suite or otherwise delivers extended infusion services rather than only episodic injections.

For two of the top biologics this clinician is a national high‑volume outlier: J3262 ranks #26 of 618 providers nationally (96th percentile; notably above typical national volume for this code) and J1745 ranks #39 of 1352 providers nationally (97th percentile; notably above typical national volume for this code). Those ranks position the provider as a major national participant for tocilizumab and infliximab administration, which may indicate either a large local referral base for infusions or a specialized infusion service.

Other biologics and biosimilars show more typical competitive standing: J0129 ranks #266 of 1221 providers nationally (78th percentile; typical, unremarkable volume for this code) and Q5104 (infliximab‑abda biosimilar) ranks #40 of 178 providers nationally (78th percentile; typical, unremarkable volume for this code). These mid‑to‑upper percentile positions suggest the provider is above average but not extreme for some products, while selectively dominant for others.

Operational billing mix downplays routine E&M relative to drug and infusion revenue: 99214 generated $54.9K (2.3% of Medicare revenue) and 99213 generated $9.5K (0.4%), indicating relatively low revenue from standard office visits compared with biologic drug administration. This pattern is typical for clinicians whose practice economics are driven by high‑cost infused medications rather than visit volume.

Several infusion/administration procedure codes are statistical outliers, reinforcing intense infusion activity: 96415 (595 claims, $12.5K, 0.5%) ranks #42 of 4959 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code) and 96365 (585 claims, $27.5K, 1.2%) ranks #281 of 8873 providers nationally (97th percentile; notably above typical national volume for this code). These outlier positions imply unusually high use of extended or repeat infusion billing relative to peers and merit attention when modeling infusion capacity or cost per episode.

The NPI tenure indicates the provider has an established presence: NPI enumerated (registered) 2006-02-01 (~20 years ago), consistent with a long‑standing practice that may have developed sustained referral relationships and an established infusion operation over time. Tenure combined with the high biologic volumes suggests a stable, mature service line rather than a new or transient practice.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

27 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3262	Injection, tocilizumab, 1 mg	127,280	$10	$636.4K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	14,500	$30	$493K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	14,240	$30	$370.1K
J9312	Injection, rituximab, 10 mg	4,400	$60	$246.4K
J1602	Injection, golimumab, 1 mg, for intravenous use	21,050	$10	$210.5K
J0897	Injection, denosumab, 1 mg	6,360	$20	$114.5K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	3,990	$30	$107.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	650	$90	$54.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	500	$90	$47.4K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	590	$50	$27.5K

Showing 1–10 of 27

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 27 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Utah Distribution

Corey Walker — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Utah

Full comparison — all codes billed, vs. state median

27 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J3262	1	10	70,740	$1	$328K
J0129	1	10	7,880	$30	$287.1K
J9312	1	10	3,050	$60	$177.4K
J1745	1	10	4,400	$30	$137.1K
J1602	1	10	11,950	$10	$127.5K
Q5104	2	10	3,550	$30	$99.1K
J0897	12	70	1,920	$20	$67.2K
96413	3	50	100	$90	$13.8K
99214	118	4,080	80	$80	$11.6K
99215	1,102	1,190	40	$110	$7.5K

Showing 1–10 of 27

Related Providers

Other providers that share a Tax Identification Number (TIN) with Corey Walker, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ihc Health Services, Inc.	UT	Children's Hospital	$0	$129.5M
Ihc Health Services, Inc.	UT	General Acute Care Hospital	$0	$68.7M
Ihc Health Services, Inc.	UT	General Acute Care Hospital	$0	$65.8M
Ihc Health Services Inc	UT	General Acute Care Hospital	$0	$54.1M
Ihc Health Services, Inc.	UT	General Acute Care Hospital	$0	$44.3M
Ihc Health Services Inc	UT	Home Infusion Therapy Pharmacy	$0	$38.1M
Ihc Health Services Inc	UT	Durable Medical Equipment & Medical Supplies	$0	$26.9M
Ihc Health Services Inc	UT	General Acute Care Hospital	$0	$25.3M
Ihc Health Services, Inc.	UT	Clinical Medical Laboratory	$2.7M	$17.9M
Ihc Health Services, Inc.	UT	General Acute Care Hospital	$0	$20.4M

Nearby Providers

Other providers in the same ZIP code as Corey Walker, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mountain Division - Cvh, LLC	UT	General Acute Care Hospital	$0	$4.4M
Team Recovery	UT	Substance Abuse Rehabilitation Facility	$0	$3M
Cache County School District	UT	Local Education Agency (LEA)	$0	$2.9M
Ihc Health Services Inc	UT	Internal Medicine Physician	$0	$2.8M
Rocky Mountain Emergency Specialists LLC	UT	Emergency Medicine Physician	$0	$2.4M
Bear River District Health Dept	UT	Public Health or Welfare Agency	$99.1K	$2.1M
Bear River District Health Dept	UT	Addiction (Substance Use Disorder) Counselor	$0	$1.7M
Daren Gehring	UT	Pediatric Dentistry	$0	$1M
Kenneth Fryer	UT	Pediatric Dentistry	$0	$958K
Cache Valley Surgery Center, LLC	UT	Ambulatory Surgical Clinic/Center	$903.2K	$0

Corey Walker — Billing Profile & Reimbursement Data

Sign up for Corey Walker — Billing Profile & Reimbursement Data policy alerts

Corey Walker — Billing Profile & Reimbursement Data

Sign up for Corey Walker — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References